TABLE 1.
Participant characteristics by treatment preferencea
| Variable | All (N = 761) N (Column %) | Treatment Preference | ||||
|---|---|---|---|---|---|---|
| AS/WW (N = 417) N (Row %) | RP (N = 198) N (Row %) | EBRT (N = 69) N (Row %) | BRAC (N = 77) N (Row %) | P Value | ||
| Age in years (median, IQR) | (62, 11) | (63, 9) | (58, 11) | (66, 7) | (61, 11) | <.001 |
| Age by category | <.001 | |||||
| <50 | 51 (6.7) | 17 (33.3) | 24 (47.1) | 2 (3.9) | 8 (15.7) | |
| 50–59 | 249 (32.7) | 121 (48.6) | 91 (36.5) | 10 (4.0) | 27 (10.8) | |
| 60–69 | 373 (49) | 219 (58.75) | 78 (20.9) | 43 (11.5) | 33 (8.8) | |
| 70+ | 88 (11.6) | 60 (68.2) | 5 (5.7) | 14 (15.9) | 9 (10.2) | |
| Days from diagnosis (median, IQR) | (25, 14) | (26, 16) | (25, 14) | (25, 9) | (23, 17) | .13 |
| Race | .02 | |||||
| White | 623 (81.9) | 347 (55.7) | 150 (24.1) | 63 (10.1) | 63 (10.1) | |
| Black | 85 (11.2) | 37 (43.5) | 32 (37.6) | 5 (5.9) | 11 (12.9) | |
| Other | 53 (7) | 33 (62.3) | 16 (30.2) | 1 (1.9) | 3 (5.7) | |
| Ethnicity | .03 | |||||
| Hispanic | 93 (12.4) | 46 (49.5) | 35 (37.6) | 4 (4.3) | 8 (8.6) | |
| Non-Hispanic | 657 (87.6) | 360 (54.8) | 162 (24.7) | 66 (10.0) | 162 (24.7) | |
| Marital status | <.01 | |||||
| Married/relationship | 619 (81.4) | 330 (53.3) | 177 (28.6) | 58 (9.4) | 54 (8.7) | |
| Separated/divorced/widowed | 115 (15.1) | 71 (61.7) | 19 (16.5) | 7 (6.1) | 18 (15.7) | |
| Never married | 26 (3.4) | 15 (57.7) | 2 (7.7) | 4 (15.4) | 5 (19.2) | |
| Education | .02 | |||||
| ≤High school | 164 (21.6) | 83 (50.6) | 50 (30.5) | 13 (7.9) | 18 (11.0) | |
| Some college | 251 (33.1) | 137 (54.6) | 64 (25.5) | 26 (10.4) | 24 (9.6) | |
| College graduate | 165 (21.8) | 82 (49.7) | 41 (24.8) | 14 (8.5) | 28 (17.0) | |
| Graduate school/degree | 178 (23.5) | 112 (62.9) | 43 (24.2) | 16 (9.0) | 7 (3.9) | |
| Employment | <.001 | |||||
| Employed | 432 (57.4) | 235 (54.4) | 131 (30.3) | 25 (5.8) | 41 (9.5) | |
| Retired | 283 (37.6) | 157 (55.5) | 55 (19.4) | 41 (14.5) | 30 (10.6) | |
| Not employed/disabled | 37 (4.9) | 16 (43.2) | 12 (32.4) | 3 (8.1) | 6 (16.2) | |
| Income | .55 | |||||
| ≤$75,000 | 269 (37.9) | 144 (53.5) | 65 (24.2) | 26 (9.7) | 34 (12.6) | |
| $75,000–125,000 | 234 (100) | 134 (57.3) | 22 (9.4) | 21 (9.0) | 57 (24.4) | |
| >$125,000 | 206 (29.1) | 105 (51.0) | 66 (32.0) | 18 (8.7) | 17 (8.3) | |
| Comorbidity (Elixhauser) | .59 | |||||
| 0 | 263 (34.6) | 143 (54.4) | 72 (27.4) | 22 (8.4) | 26 (9.9) | |
| 1 | 205 (26.9) | 116 (56.6) | 56 (27.3) | 12 (5.9) | 21 (10.2) | |
| 2 | 114 (15) | 57 (50.0) | 29 (25.4) | 15 (13.2) | 13 (11.4) | |
| 3+ | 179 (23.5) | 101 (56.4) | 41 (22.9) | 20 (11.2) | 17 (9.5) | |
| PSA level | .03 | |||||
| ≤4 ng/mL | 82 (10.8) | 37 (45.1) | 31 (37.8) | 4 (4.9) | 10 (12.2) | |
| >4–10 ng/mL | 679 (89.2) | 380 (56.0) | 167 (24.6) | 65 (9.6) | 67 (9.9) | |
a
Number of respondents within each category may not be the same as total due to missing data.
Abbreviations: AS/WW indicates active surveillance/watchful waiting; RP, radical prostatectomy; EBRT, external beam radiotherapy; BRAC, brachytherapy; PSA, prostate-specific antigen.